Combatting Diet Related Non-Communicable Diseases through Enhanced Surveillance

Imperial College London0 个研究点目标入组 200 人2023年10月24日

概览

阶段: 未知
干预措施: 未指定
疾病 / 适应症: Healthy individuals at risk of developing non-communicable diseases (heart disease, type 2 diabetes, cancer).
发起方: Imperial College London
入组人数: 200
状态: 进行中（未招募）
最后更新: 2年前

暂无简介。

注册库

who.int

开始日期

2023年10月24日

结束日期

2024年9月30日

最后更新

2年前

研究类型

Observational

性别

All

发起方

•1\. Male and Female aged 18\-65 years old
•2\. Individuals at high risk of developing a non\-communicable disease assessed through the metabolic risk score:
•2\.1\. Overweight or obesity (BMI greater than 25 kg/m²) plus any two of the four factors:
•2\.2\. Raised triglycerides: \= 100 mg/dL (1\.7 mmol/L)
•2\.3\. Reduced HDL cholesterol: \< 40 mg/dL (1\.03 mmol/L) in males or \< 50 mg/dL (1\.29mmol/L) in females.
•2\.4\. Raised blood pressure: systolic BP \= 130 or diastolic BP \= 85 mm Hg.
•2\.5\. Raised fasting plasma glucose (FPG): \= 90 mg/dL (5\.0 mmol/L).
•3\. Current smokers

•1\. Suffer from the following conditions: type 2 diabetes, chronic gastrointestinal conditions (Crohn’s disease, irritable bowel syndrome, ulcerative colitis etc.), acute infectious diseases, cardiovascular diseases, hypertension, autoimmune conditions,
•2\. Were on antibiotic treatment in the 12 weeks preceding enrolment of the clinical trial,
•3\. Pregnant or currently breastfeeding,
•4\. Are currently participating in other clinical trials or participated in another trial within the last 12 weeks,
•5\. Require any medical interventions during the study period,
•6\. Cannot give consent by yourself.